Surgery in Hemophilia. A general view over a 4-year centre experience



Santos, Alexandra. Diniz, M. João. Antunes, Margarida Imunohemotherapy Service — Hospital São José (Lisbon, Portugal)

INTRODUCTION

- Patients with Hemophilia A or B of all severities are at increased bleeding risk following injury of any origin.
- A surgical intervention may be elective or of an emergency nature.
 It can be *major* or *minor*, according to the perceived or proven bleeding risk.
- When planning a potentially dangerous procedure, we should consider the risks and benefits and very carefully take into account the patient's age, life expectancy and immunologic status.
- The patient should be managed in a hemophilia centre, where a comprehensive team approach can be provided.
- The aim of our study is to get a general view on all surgeries performed at Hospital São José since 2006, in these patients.

METHODS

- Hospital patient's medical records where reviewed from January 2006 to October 2010.
- Data collected on: age, type of hemophilia, surgical procedure, n.º of hospitalization days, hemostatic outcome, adverse events and other complications.

CONCLUSIONS

- Hemophilia is not a contraindication for surgery, but adequate clotting factor correction is required.
- Factor dose and duration of replacement therapy depend on the type of intervention and severity of hemophilia.
- 21 patients (4 with inhibitor) underwent 24 surgeries (15 *major* and 9 *minor*) since 2006.
- Overall hemostatic outcome was very good.
- Patient 8 had an hemoperitoneum at day 4 and was submitted to laparoscopic revision; patients 10 and 20 developed a suture hematoma.
- The hemophiliac patient with inhibitor is at higher risk for management of bleeding control. Patient 13 needed sequential bypassing therapy.
- Despite the economic impact and need for Hospital's Clinical Board approval, a rising number of elective surgeries in the inhibitor subpopulation are being performed, resulting in a better quality of life.
- Weight control in the hemophiliac patient is crucial not only to prevent other medical associated diseases and joint damage but also for reducing the cost of treatment.
- No thromboembolic adverse events were reported.

RESULTS

- 21 patients identified
- Median age at surgery: 43 years-old (9-68)
- Patients are caracterized according to the type of Hemophila in Table 1

Table 1

Type of Hemophila	Number of patients (21)		
A severe	14 (4 w/ inhibitor)		
A moderated	2		
A mild	1		
Carrier	1		
B severe	1		
B moderated	1		
B mild	1		

Table 2

	24 surgeries	Elective	Emergency setting
Major	15	11	4
Minor	9	8	1

- 24 surgeries: 15 major and 9 minor (Table 2)
- pd FVIII/FIX concentrates were used in 16 procedures and rFVIII/FIX concentrates were used in 4. All administrations were in bolus

Table 3 – *Major* surgical procedures in HA and HB patients:

Patient	Type of Hemophilia	Procedure	Total IU FVIII/FIX	Hospitalization days	Hemostatic outcome	Adverse events
1	Α	Knee arthroplasty	123000	21	Excellent	_
2	Α	Knee arthroplasty	118000	19	Excellent	_
3	Α	Herniotomy	28000	10	Excellent	_
4	Α	Hemorrhoidectomy	45000	7	Excellent	_
5	Α	Knee arthroplasty	45000	8	Excellent	_
6	Α	Knee arthroplasty	92000	18	Good	_
7	Α	Radical prostatectomy	79500 57000*	14	Good	Inhibitor** Urosepsis‡
8	Α	Apendicectomy	70500	14	Good	_
9	Α	Open femur reduction	55000	15	Excellent	_
10	В	Hydrocel	155000	18	Good	_
11	В	Thigh skin graft	185000	14	Excellent	_

^{*} aCCP; **inhibitor at day 10; ‡ urosepsis at day 14, transfered to ICU and died 3 months latter (patient w/ Diabetes Mellitus type 2).

Table 4 – *Major* surgery in patients with inhibitor:

Patient	Type of Hemophilia	Procedure	Total dose rFVIIa*/ aPCC° (μg*/IU°)	Hospitalization days	Hemostatic outcome	Adverse events
12	Α	Laparoscopic colecistectomy	287*	7	Excellent	_
13	Α	Apendicectomy with segmentar ileotomy	898*/156000°	26	Good	_
14	Α	Apendicectomy	125000°	13	Good	_
15	Α	Total nephrectomy	660*	17	Good	_

Table 5 – *Minor* surgical procedures in HA and HB patients:

Patient	Type of Hemophilia	Procedure*	Total IU FVIII/FIX	Hospitalization days	Hemostatic outcome	Adverse events
16	Α	Tonsilectomy with adenoidectomy	65000	5	Excellent	_
17	Α	Multiple dental extractions	3000	0	Excellent	_
6	Α	Skin debridement Skin graft	15000 23000	1 3	Good Good	_ _
18	Α	Femur osteotomy	17000	11	Good	_
19	Α	Multiple dental extractions	22000	4	Excellent	_
20	Α	Uretral stent Uretral stent	13000 13000	2 4	Excellent Excellent	
21	В	Prostatic braquiterapy	9000	2	Excellent	_

* Synoviarthesis excluded